FAR08

FAR08 is an experimental small molecule androgen receptor (AR) antagonist developed as part of a series of 4,4-dimethylimidazolidin-2-one-based compounds (FAR01–FAR11). It was designed as a structural analog of the second-generation AR antagonist enzalutamide, featuring a flexible imidazolidinone pharmacophore in place of the rigid thiohydantoin ring found in the parent drug. This modification, along with the introduction of a methylene spacer between the pharmacophore and the aromatic ring, was intended to investigate the role of molecular flexibility and intramolecular non-covalent interactions in AR binding affinity. FAR08 is primarily researched for its potential in treating prostate cancer, particularly castration-resistant prostate cancer (CRPC), where continued AR signaling drives disease progression despite androgen deprivation therapy.